問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Endocrinology

Digestive System Department

Division of Nephrology

更新時間：2023-09-19

林嘉鴻Lin, Jia-Hong
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • adronlin@cgmh.org.tw

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林嘉鴻

List

19Cases

2021-08-31 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Not yet recruiting9Sites

Recruiting9Sites

2025-01-01 - 2030-01-31

Phase III

Active
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non- alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis

  • Condition/Disease

    cirrhosis

  • Test Drug

    N/A

Participate Sites
11Sites

Recruiting11Sites

2025-01-01 - 2032-12-31

Phase III

Active
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non- cirrhotic non-alcoholic steatohepatitis/metabolic dysfunction- associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis

  • Condition/Disease

    liver fibrosis

  • Test Drug

    N/A

Participate Sites
11Sites

Recruiting11Sites

2026-02-01 - 2029-02-24

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2022-04-05 - 2024-09-30

Phase III

Completed
A 52-week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist. COMBINE 2

  • Condition/Disease

    Type 2 Diabetes

  • Test Drug

    IcoSema

Participate Sites
5Sites

Not yet recruiting4Sites

Terminated1Sites

2020-10-01 - 2024-12-31

Phase III

Completed
Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease

  • Condition/Disease

    Diabetes Mellitus, Type 2/Peripheral Arterial Disease

  • Test Drug

    Semaglutide 1.34 mg/ml / placebo

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated4Sites

2024-11-05 - 2027-02-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2017-10-01 - 2021-03-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    CS02 Tablet

Participate Sites
13Sites

Recruiting2Sites

Terminated10Sites

陳清助
China Medical University Hospital-Taipei

未分科

陳涵栩
Taipei Veterans General Hospital

Division of Endocrinology

2007-10-01 - 2008-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-08-01 - 2019-01-31

Phase III

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes PRONTO-T2D

  • Condition/Disease

    Type 2 Diabetes

  • Test Drug

    LY900014

Participate Sites
5Sites

Terminated5Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB